/Finerenone in CKD and Type 2 Diabetes: The FIDELIO-DKD Trial
Finerenone in CKD and Type 2 Diabetes: The FIDELIO-DKD Trial
0:00 / 5:07
Introduction
0:00 - 0:38
An introduction to the FIDELIO-DKD trial and finerenone.
Mechanism and Rationale
0:38 - 1:19
The mechanism of action of nonsteroidal mineralocorticoid receptor antagonists.
Trial Design and Participants
1:19 - 1:59
Trial design, including patient inclusion and background RAS blockade.
Baseline Patient Profile
1:59 - 2:34
Baseline demographics and clinical characteristics of participants.
Primary Kidney Outcomes
2:34 - 3:13
Primary kidney outcome results and Kaplan-Meier curves.
Secondary Cardiovascular Benefits
3:13 - 3:50
Cardiovascular risk reduction and early benefit separation.
Safety and Hyperkalemia Profile
3:50 - 4:32
Safety findings with a focus on hyperkalemia management.
Clinical Significance
4:32 - 5:07
Summary of clinical significance and the new treatment paradigm.